Skip to Main Content
Walk To Defeat ALS

Search Our Site

Talk to Us

We're just a phone call or mouse click away. Find help here.

Share Print

Sanofi Sells Rilutek to Covis Pharma Sarl

April 4, 2013

Today, Covis Pharma Sarl, a Switzerland-based specialty pharmaceutical company, announced its agreement with sanofi-aventis U.S. LLC to acquire rights to Rilutek® (riluzole), which as you know is the only drug approved by the U.S. Food and Drug Administration (FDA) to treat ALS. Other compounds were also included in this aggregate sale. This international company has a U.S. affiliate, Covis Pharmaceuticals, in Cary, North Carolina.

More information on the sale of Rilutek can be found here.

The ALS Association - 1275 K Street NW - Suite 250 - Washington, DC 20005
All content and works posted on this website are owned and copyrighted by The ALS Association. ©2014

Lou Gehrig® used with permission of the Rip Van Winkle Foundation / www.LouGehrig.com